Peripheral neuropathy encompasses diverse conditions—diabetic, idiopathic, chemotherapy-induced, ischaemic—characterised by progressive nerve fibre loss, demyelination, and sensorimotor dysfunction.
Peripheral neuropathy encompasses diverse conditions—diabetic, idiopathic, chemotherapy-induced, ischaemic—characterised by progressive nerve fibre loss, demyelination, and sensorimotor dysfunction. Stem cell therapies exploit multiple pathways: placental mesenchymal stem cells (MSCs) secrete neurotrophic factors (NGF, GDNF, VEGF) that promote nerve regeneration and angiogenesis; neurogenic cells differentiate into functional neurons to replace damaged fibres; exosomes deliver growth factor cargo directly into affected peripheral tissues. The rationale combines neuroprotection (halting further degeneration), neuroregenerative repair (sprouting of surviving axons), and vascular restoration (improving ischaemic neuropathy). Forty-six registered trials investigate efficacy across neuropathy subtypes; eight actively recruit, indicating expanding clinical capacity and commercial interest.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €2,300–€4,600 (dvcstem.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Neurogenic Cells, Exosomes |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 46 · 8 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Published trials of intra-muscular or systemic placental MSC injection report improved sensory function in 45–60% of diabetic neuropathy patients and pain reduction in 50–70% of painful neuropathy cohorts. Electrophysiological endpoints (nerve conduction velocity, F-wave latency) show modest improvement in responders. A phase II diabetic neuropathy trial (80 patients) found reduction in neuropathic pain score by 40–50% at 12 months in treated versus sham-injected groups. Neurogenic cell therapies are less extensively studied; early trials show safety signals but limited efficacy data. Exosome therapy is emerging with small proofs-of-concept suggesting reduced pain and improved sensation in chemotherapy-induced neuropathy.
Depending on assessment, a Peripheral Neuropathy protocol may draw on:
Neuropathy cell therapy costs €4,000–6,500 depending on delivery method and cell source. Systemic intravenous MSC infusion (€4,500–5,500) is most accessible. Intra-muscular or targeted intrathecal injection (€5,500–7,000) delivers higher local concentration but requires specialised placement. Exosome therapy (€4,000–5,500) is emerging with competitive pricing. Multiple infusions over 3–6 months are often recommended, doubling total cost to €8,000–13,000. Insurance rarely reimburses; out-of-pocket expense is standard globally, though some regional trials offer free or subsidised access to enrolled patients.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Peripheral Neuropathy cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Peripheral Neuropathy.
Full Peripheral Neuropathy FAQ → · Peripheral Neuropathy cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية